Nemus Bioscience, Inc. has entered an agreement with Albany Molecular Research Inc. for the development and manufacture of Nemus’ cannabinoid-based API. AMRI will leverage its process chemistry expertise in the synthesis and formulation of Nemus’ prodrug of tetrahydrocannabinol (THC). This molecule forms the basis of NB1111, which is in development for the treatment of glaucoma. “Advancing our lead therapeutic candidates into the API manufacturing stage is a major milestone ...